Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 1/2 4Phase NA 2Phase 3 1Phase 2/3 1Phase 1 1

Status

Recruiting 2Active not recruiting 2Terminated 1

Sponsor Class

OTHER 5

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 5

Conditions

Breast Neoplasms 558Carcinoma, Non-Small-Cell Lung 514Prostatic Neoplasms 336Colorectal Neoplasms 273Neoplasms 269Multiple Myeloma 267Leukemia, Myeloid, Acute 225Squamous Cell Carcinoma of Head and Neck 217Lung Neoplasms 210Neoplasm Metastasis 205Carcinoma, Hepatocellular 198Melanoma 175Triple Negative Breast Neoplasms 174Pancreatic Neoplasms 171Recurrence 153Ovarian Neoplasms 152Lymphoma 142Glioblastoma 136Brain Neoplasms 134Sarcoma 131Carcinoma, Renal Cell 128Lymphoma, Large B-Cell, Diffuse 126Leukemia, Lymphocytic, Chronic, B-Cell 126Head and Neck Neoplasms 124Stomach Neoplasms 123Precursor Cell Lymphoblastic Leukemia-Lymphoma 110Rectal Neoplasms 109Myelodysplastic Syndromes 104Uterine Cervical Neoplasms 100Urinary Bladder Neoplasms 100

Interventions

Taxes 2Radiotherapy 2Losartan 2Gemcitabine 2Albumin-Bound Paclitaxel 2dehydroftorafur 1X-Rays 1Specimen Handling 1Radiotherapy, Intensity-Modulated 1Radiation 1Oxaliplatin 1Leucovorin 1Irinotecan 1Fluorouracil 1Capecitabine 1Anesthesia, General 1Anesthesia 13-(5-fluorobenzofuran-3-yl)-4-(5-methyl-5H-(1,3)dioxolo(4,5-f)indol-7-yl)-pyrrole-2,5-dione 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 2 × Pancreatic Adenocarcinoma × 1 year × Clear all
NCT05077800 2026-04-13

FOLFIRINOX + Elraglusib + Losartan In Pancreatic Cancer

Massachusetts General Hospital

Phase 2 Active not recruiting
70 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

NCT05624918 2026-04-08

A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma

Big Ten Cancer Research Consortium

Phase 2 Recruiting
38 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

NCT04539808 2026-01-14

NeoOPTIMIZE: Early Switching of mFOLFIRINOX or Gemcitabine/Nab-Paclitaxel Before Surgery for the Treatment of Resectable, Borderline Resectable, or Locally-Advanced Unresectable Pancreatic Cancer

OHSU Knight Cancer Institute

Phase 2 Active not recruiting
42 enrolled 13 charts
Gastrointestinal

Pancreatic Adenocarcinoma

NCT06149689 2025-08-07

PTCA199-7

Fudan University

Phase 2 Recruiting
30 enrolled
Gastrointestinal

Pancreatic Adenocarcinoma

NCT04992507 2025-07-10

Impact of Total Intravenous Anesthesia Following Cancer Surgery, TIVACS Study

Ohio State University Comprehensive Cancer Center

Phase 2 Terminated
8 enrolled 7 charts
Gastrointestinal

Pancreatic Adenocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡